He argues Lilly's tirzepatide profits give it a big head start to pour billions back into research. This is an investor's opinion, not a forecast from Lilly.
Recap by typeshit. Post by James Camp 🛠,🛠 on X.
The chain says it is exploring concepts including grilled items aimed at GLP-1 users, a sign of how the drugs are shifting food businesses.
Ahead of results, Kalkine looks at how costly late-stage trials for Amgen's monthly obesity shot MariTide weigh on the outlook.
A short post says demand for GLP-1s, psychedelics and testosterone is meeting commercial interests, calling it a big shift.
A beauty take that waves off pricey LA peptide and salmon sperm serums, saying better anti-aging habits are found closer to home.
Researchers led by J Petersen and Christoffer Clemmensen at the University of Copenhagen report results from pairing the two obesity drugs. Full findings are in the paper.
The obesity doctor responds to claims a pharmacist made about GLP-1 medications. Details of the claims aren't given, so tap through to hear his take.
Loading…